GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001604921 | Liver | HCC | cell growth | 269/7958 | 482/18723 | 1.84e-09 | 5.35e-08 | 269 |
GO:003253522 | Liver | HCC | regulation of cellular component size | 217/7958 | 383/18723 | 1.28e-08 | 3.14e-07 | 217 |
GO:000155821 | Liver | HCC | regulation of cell growth | 228/7958 | 414/18723 | 1.34e-07 | 2.55e-06 | 228 |
GO:003134611 | Liver | HCC | positive regulation of cell projection organization | 193/7958 | 353/18723 | 2.28e-06 | 3.08e-05 | 193 |
GO:001072011 | Liver | HCC | positive regulation of cell development | 155/7958 | 298/18723 | 5.39e-04 | 3.48e-03 | 155 |
GO:006056011 | Liver | HCC | developmental growth involved in morphogenesis | 124/7958 | 234/18723 | 7.37e-04 | 4.47e-03 | 124 |
GO:001097511 | Liver | HCC | regulation of neuron projection development | 220/7958 | 445/18723 | 1.68e-03 | 8.78e-03 | 220 |
GO:004867511 | Liver | HCC | axon extension | 67/7958 | 120/18723 | 2.17e-03 | 1.09e-02 | 67 |
GO:199013811 | Liver | HCC | neuron projection extension | 92/7958 | 172/18723 | 2.31e-03 | 1.14e-02 | 92 |
GO:004858811 | Liver | HCC | developmental cell growth | 121/7958 | 234/18723 | 2.68e-03 | 1.28e-02 | 121 |
GO:00507674 | Liver | HCC | regulation of neurogenesis | 181/7958 | 364/18723 | 3.00e-03 | 1.40e-02 | 181 |
GO:004577321 | Liver | HCC | positive regulation of axon extension | 27/7958 | 42/18723 | 3.60e-03 | 1.60e-02 | 27 |
GO:00507693 | Liver | HCC | positive regulation of neurogenesis | 116/7958 | 225/18723 | 3.67e-03 | 1.63e-02 | 116 |
GO:003030711 | Liver | HCC | positive regulation of cell growth | 88/7958 | 166/18723 | 3.95e-03 | 1.74e-02 | 88 |
GO:00083614 | Liver | HCC | regulation of cell size | 95/7958 | 181/18723 | 4.15e-03 | 1.81e-02 | 95 |
GO:00305164 | Liver | HCC | regulation of axon extension | 52/7958 | 95/18723 | 1.07e-02 | 3.97e-02 | 52 |
GO:000166721 | Liver | HCC | ameboidal-type cell migration | 226/7958 | 475/18723 | 1.35e-02 | 4.81e-02 | 226 |
GO:004592711 | Liver | HCC | positive regulation of growth | 128/7958 | 259/18723 | 1.41e-02 | 4.99e-02 | 128 |
GO:0016049112 | Thyroid | PTC | cell growth | 225/5968 | 482/18723 | 4.75e-12 | 2.07e-10 | 225 |
GO:0031346110 | Thyroid | PTC | positive regulation of cell projection organization | 173/5968 | 353/18723 | 1.09e-11 | 4.40e-10 | 173 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MEGF8 | SNV | Missense_Mutation | | c.4777N>T | p.Thr1593Ser | p.T1593S | Q7Z7M0 | protein_coding | tolerated(0.74) | benign(0.005) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
MEGF8 | SNV | Missense_Mutation | novel | c.3235N>T | p.Arg1079Cys | p.R1079C | Q7Z7M0 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-A2-A0T1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Targeted Molecular therapy | herceptin | SD |
MEGF8 | SNV | Missense_Mutation | novel | c.6919C>A | p.Arg2307Ser | p.R2307S | Q7Z7M0 | protein_coding | tolerated(0.1) | possibly_damaging(0.77) | TCGA-A8-A07F-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
MEGF8 | SNV | Missense_Mutation | rs760533124 | c.1573N>A | p.Val525Ile | p.V525I | Q7Z7M0 | protein_coding | tolerated(0.18) | benign(0.106) | TCGA-A8-A09Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
MEGF8 | SNV | Missense_Mutation | novel | c.3763N>A | p.Ala1255Thr | p.A1255T | Q7Z7M0 | protein_coding | tolerated(0.08) | possibly_damaging(0.446) | TCGA-AC-A2QI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
MEGF8 | SNV | Missense_Mutation | novel | c.7159N>A | p.Asp2387Asn | p.D2387N | Q7Z7M0 | protein_coding | tolerated(0.21) | probably_damaging(0.989) | TCGA-AC-A5XU-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | letrozole | SD |
MEGF8 | SNV | Missense_Mutation | | c.4009N>G | p.Thr1337Ala | p.T1337A | Q7Z7M0 | protein_coding | tolerated(0.13) | possibly_damaging(0.554) | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
MEGF8 | SNV | Missense_Mutation | rs758529363 | c.1603C>T | p.Arg535Trp | p.R535W | Q7Z7M0 | protein_coding | tolerated(0.19) | possibly_damaging(0.676) | TCGA-AR-A250-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
MEGF8 | SNV | Missense_Mutation | | c.6002N>C | p.Cys2001Ser | p.C2001S | Q7Z7M0 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |
MEGF8 | SNV | Missense_Mutation | rs748260455 | c.7826N>T | p.Ser2609Leu | p.S2609L | Q7Z7M0 | protein_coding | deleterious(0.01) | possibly_damaging(0.692) | TCGA-BH-A0BZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | CR |